Methodology of a new inflammatory arthritis registry: TReasure

Basit Öğe Kaydı
dc.authoridYILMAZ, Sedat/0000-0002-4691-3417
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridKaymaz-Tahra, Sema/0000-0001-5706-4943
dc.authoridATAGUNDUZ, MEHMET PAMIR/0000-0002-6393-7461
dc.authoridTASCILAR, Koray/0000-0002-8109-826X
dc.authoridAtes, Askin/0000-0003-1966-3333
dc.authoridmercan, ridvan/0000-0003-1537-2192
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorTascilar, Etem Koray
dc.contributor.authorErtenli, Ali Ihsan
dc.contributor.authorDalkilic, Huseyin Ediz
dc.contributor.authorBes, Cemal
dc.contributor.authorKucuksahin, Orhan
dc.contributor.authorKasifoglu, Timucin
dc.date.accessioned2024-09-18T20:55:48Z
dc.date.available2024-09-18T20:55:48Z
dc.date.issued2018
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.en_US
dc.identifier.doi10.3906/sag-1807-200
dc.identifier.endpage861en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid30119164en_US
dc.identifier.scopus2-s2.0-85051791581en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage856en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1807-200
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12059
dc.identifier.volume48en_US
dc.identifier.wosWOS:000441766000023en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectspondyloarthritisen_US
dc.subjectdisease-modifying antirheumatic drugsen_US
dc.subjectregistryen_US
dc.subjectTReasureen_US
dc.titleMethodology of a new inflammatory arthritis registry: TReasureen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
76.6 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu